AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2021
Mar 10, 2021
30751_dirs_2021-03-10_0f6e8fbd-0cd0-4652-b443-082d61cfa8c0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2021-03-08
Reporting Person: Larkin Finbar (SVP, Technical Operations)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-08 | Ordinary Shares | S | 1509 | $161.603 | Disposed | 16519 | Direct |
Footnotes
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $161.5994 to $161.6046. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.